Современные представления о гиперактивном мочевом пузыре у женщин. Стратегия выбора лекарственной терапии

1. Van Gool J.D., de Jonge G.A. Urge syndrome and urge incontinence. Arch Dis Child. 1989; 64(11): 1629-34. https://dx.doi.org/10.1136/adc.64.11.1629.
2. Kondo A., Kato K., Takita T., Otani T. Holding postures characteristic of unstable bladder. J Urol. 1985 Oct; 134(4): 702-4. https://dx.doi.org/10.1016/s0022-5347(17)47396-4.
3. Bulmer P., Abrams P. The unstable detrusor. Urol Int. 2004; 72(1): 1-12. https://dx.doi.org/ 10.1159/000075265.
4. Ромих В.В., Борисенко Л.Ю., Захарченко А.В. Мирабегрон. Состоится ли революция в лечении гиперактивного мочевого пузыря? Урология. 2015; 5: 80-7.
5. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004; 64 (6 Suppl. 1): 2-6. https://dx.doi.org/10.1016/j.urology.2004.10.047.
6. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9): 760-6. https://dx.doi.org/10.1046/j.1464-410x.2001.02228.x.
7. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R., Hunt T.L., Wein A.J. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6): 327-36. https://dx.doi.org/10.1007/s00345-002-0301-4.
8. Coyne K.S., Wein A.J., Tubaro A., Sexton C.C., Thompson C.L., Kopp Z.S., Aiyer L.P. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009; 103 Suppl 3: 4-11. https://dx.doi.org/10.1111/j.1464-410X.2009.08371.x.
9. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., Wein A.; Standartisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2): 167-78. https://dx.doi.org/10.1002/nau.10052.
10. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., Wein A., Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61(1):37-49. https://dx.doi.org/10.1016/s0090-4295(02)02243-4.
11. Haylen B.T., de Ridder D., Freeman R.M., Swift S.E. Berghmans B. et al., International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29(1): 4-20. https://dx.doi.org/10.1002/nau.20798.
12. Morrison J., Steers W.D., Brading A.F. et al. Neurophysiology and neuropharmacology. In: Abrams P., Cardozo L., Khoury, Wein A., eds. Incontinence. 2nd ed. Plymouth, England: Health Publications; 2002: 86-163.
13. Yoshimura N., Chancellor M.B. Current and future pharmacological treatment for overactive bladder. J Urol. 2002; 168(5): 1897-913. https://dx.doi.org/10.1097/01.ju.0000031061.70559.40.
14. Igawa Y., Aizawa N., Homma Y. β3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010; 51(12): 811-8. https://dx.doi.org/10.4111/kju.2010.51.12.811.
15. Schäfer W., Abrams P., Liao L., Mattiasson A., Pesce F., Spangberg A., Sterling A.M., Zinner N.R., van Kerrebroeck P., International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002; 21(3): 261-74. https://dx.doi.org/10.1002/nau.10066.
16. Cho K.J., Kim H.S., Koh J.S. , Kim J.C. Evaluation of female overactive bladder using urodynamics: Relationship with female voiding dysfunction. Int Braz J Urol. 2015; 41(4): 722-8. https://dx.doi.org/10.1590/S1677-5538.IBJU.2014.0195.
17. Digesu G.A., Khullar V., Cardozo L., Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003: 22(2): 105-8. https://dx.doi.org/10.1002/nau.10099.
18. Robinson D., Staskin D., Laterza R.M., Koelbl H. Defining female voiding dysfunction: ICI-RS 2011. Neurourol Urodyn. 2012; 31(3): 313-6. https://dx.doi.org/10.1002/nau.22213.
19. Giarenis I., Zacchè M., Robinson D., Cardozo L. Is there any association between urodynamic variables and severity of overactive bladder in women with idiopathic detrusor overactivity? Neurourol Urodyn. 2017; 36(3): 780-3. https://dx.doi.org/10.1002/nau.23023.
20. Serati M., Topazio L., Bogani G., Costantini E., Pietropaolo A., Palleschi G., Carbone A., Soligo M., Del Popolo G., Marzi V.L., Salvatore S., Agro E.F. Urodynamics useless before surgery for female stress urinary incontinence: Are you sure? Results from a multicenter single nation database. Neurourol Urodyn. 2016; 35(7): 809-12. https://dx.doi.org/10.1002/nau.22804.
21. Holmgren C., Nilsson S., Lanner L., Hellberg D. Frequency of de novo urgency in 463 women who had undergone the tension-free vaginal tape (TVT) procedure for genuine stress urinary incontinence--a long-term follow-up. Eur J Obstet Gynecol Reprod Biol. 2007; 132(1): 121-5. https://dx.doi.org/10.1016/j.ejogrb.2006.04.012.
22. Lleberia-Juanós J., Bataller-Sánchez E., Pubill-Soler J., Mestre-Costa M., Ribot-Luna L., Checa Vizcaíno M.A. De novo urgency after tension-free vaginal tape versus transobturator tape procedure for stress urinary incontinence. Eur J Obstet Gynecol Reprod Biol. 2011; 155(2): 229-32. https://dx.doi.org/10.1016/j.ejogrb.2010.12.026.
23. Каприн А.Д., Аполихин О.И., Сивков А.В., Ромих В.В., Захарченко А.В., Пантелеев В.В., Ромих Ф.Д. Ботулинотерапия в современной урологии. Медицинский совет. 2016; 10: 130-9.
24. Борисенко Л.Ю., Ромих В.В., Захарченко А.В., Пантелеев В.В., Костин А.А., Аполихин О.И., Сивков А.В. Результаты исследования метода биологической обратной связи с тестовой электростимуляцией мышц тазового дна в качестве монотерапии и в сочетании с экстракорпоральной магнитной стимуляцией мышц тазового дна при функциональной инфравезикальной обструкции. Экспериментальная и клиническая урология. 2019; 2: 146-51.
25. Касян Г.Р., Гвоздев М.Ю., Коноплянников А.Г., Пушкарь Д.Ю. Недержание мочи у женщин. Методические рекомендации №4 ДЗ города Москвы. М.: АБВ-пресс. 2017; 51 с.
26. Khasriya R., Khan S., Lunawat R., Bishara S., Bignall J., Malone-Lee M., Ishii H., O'Connor D., Kelsey M., Malone-Lee J. The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with low urinary tract symptoms without acute frequency and dysuria. J Urol. 2010; 183(5):1843-7. https://dx.doi.org/10.1016/j.juro.2010.01.008.
27. Foxman В., Valdez R.B., Brock R.H. Childhood enuresis: prevalence, perceived impact and presented treatments. Pediatrics 1986; 77(4): 482-7.
28. Пугачев А.Г., Ромих В.В., Алферов С.М. Клинические особенности функциональных нарушений мочеиспускания в детском возрасте. Лечащий врач. 2004; 9: 35-8.
29. Steers W.D., Herschorn S., Kreder K.J., Moore K., Strohbehn K., Yalcin I., Bump R.C. Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007; 100(2): 337-45. https://dx.doi.org/10.1111/j.1464-410X.2007.06980.x.
30. Vella M., Duckett J., Basu M. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19(7): 961-4. https://dx.doi.org/10.1007/s00192-008-0564-4.
31. Tseng L.H., Wang A.C., Chang Y.L., Soong Y.K., Lloyd L.K., Ko Y.J. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009; 28(1): 47-51. https://dx.doi.org/10.1002/nau.20583.
32. Serati M., Salvatore S., Uccella S., Cardozo L., Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009; 55(3): 713-9. https://dx.doi.org/10.1016/j.eururo.2008.06.051.
33. Robinson D., Cardoso L. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007; 100(4): 840-5. https://dx.doi.org/10.1111/j.1464-410X.2007.07162.x.
34. D'Souza A., Smith M., Miller L., Doyle J., Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008; 14: 291-301. https://dx.doi.org/10.18553/jmcp.2008.14.3.291.
35. Сычев Д.А., Отделенов В.А., Краснова Н.М., Ильина Е.С. Полипрагмазия: взгляд клинического фармаколога. Терапевтический архив. 2016; 88(12): 94-102.
36. Boustani M., Campbell N., Munger S., Fox C. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health. 2008; 4: 311-20. https://dx.doi.org/10.2217/1745509X.4.3.311.
37. O'Donnell L.K., Gnjidic D., Nahas R., Bell J., Hilmer S. Anticholinergic burden: Considerations for older adults. Journal of Pharmacy Practice and Research. 2016. https://dx.doi.org/10.1002/jppr.1303.
38. Yamazaki Y., Takeda H., Akahane M, Igawa Y., Nishizawa O., Ajisawa Y. Species differences in the distribution of beta-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol. 1998; 124: 593-9. https://dx.doi.org/10.1038/sj.bjp.0701870.
39. Otsuka A., Shinbo H., Matsumoto R., Kurita Y., Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377(4-6): 473-81. https://dx.doi.org/10.1007/s00210-008-0274-y.
40. Lindholm, P., Lose G. Terbutaline (Bricanyl) in the treatment of female urge incontinence. Urol Int. 1986; 41: 158-60.
41. Kaidoh K., Igawa Y., Takeda H., Yamazaki Y., Akahane S., Miyata H., Ajisawa Y., Nishizawa O., Andersson K.-E. Effects of selective β2 and β3-adrenoceptor agonists in detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2002; 168(3): 1247-52. https://dx.doi.org/10.1097/01.ju.0000023414.15425.5a.
42. Yamaguchi O., Chapple C.R. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26(6):752-6. https://dx.doi.org/10.1002/nau.20420.
43. Van Gelderen E., Li Q., Meijer J., Schaddelee M., Takusagawa S., Sugawarw T. An explanatory comparison of the single dose pharmacokinetics of the β3- adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009; 85(Suppl. 1): S88.
44. Chapple C., Wyndaele J., Van Kerrebroeck P., Radziszewski P., Dvorak V., Boerrigter P. Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol. 2010; (Suppl 9): 249.
45. Khullar V., Cambronero J., Angulo J., Wooning M., Blauwet M., Dorrepaal C., Martin N.E. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post-hoc analysis of a randomised European-Australian Phase 3 trial. BMC Urol. 2013; 13(1): 45. https://dx.doi.org/10.1186/1471-2490-13-45.
46. Chapple C., Kaplan S., Mitcheson H., Klecka J., Cummings J., Drogendijk T., Dorrepaal C., Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013; 63(2): 296-305. https://dx.doi.org/10.1016/j.eururo.2012.10.048.
47. Chapple C.R., Cruz F., Cardozo L., Staskin D., Herschorn S., Choudhury N., Stoelzel M., Heesakkers J., Siddiqui E. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol. 2020; 77 (1): 119-28. https://dx.doi.org/10.1016/j.eururo.2019.09.024.

Поступила 03.06.2021

Принята в печать 17.06.2021